Trimel Pharmaceuticals Corporation

Trimel Pharmaceuticals Corporation

December 02, 2011 08:00 ET

Trimel Pharmaceuticals Corporation Manufacturing Facility Receives GMP Compliance Designation

TORONTO, ONTARIO--(Marketwire - Dec. 2, 2011) - Trimel Pharmaceuticals Corporation (TSX:TRL) (the "Company" or "Trimel") announced today that Health Canada has issued a final inspection report from its audit of Trimel's Dunwin R&D/manufacturing facility, confirming that Trimel is fully compliant with Good Manufacturing Practices (GMP) for the manufacture of clinical supplies. Trimel intends to use the Dunwin facility to manufacture clinical supplies for both of its CompleoTRT and TBS-2 (Anorgasmia) products as well as the balance of its pipeline including those compounds under development with the TriVair pulmonary delivery system. Trimel has demonstrated to Health Canada that the activities it conducts at its Dunwin facility conform to the Food and Drugs Act and its associated regulations.

"Having Health Canada approve our facility is an important validation of our business strategy." said Bruce D. Brydon, Chairman and Chief Executive Officer of Trimel. "Trimel has now achieved the first step toward the commercial supply of our products with the strictest adherence to quality."

About Trimel

Trimel Pharmaceuticals Corporation (TSX:TRL): Developing Medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT, a bio-adhesive intranasal no-touch Testosterone gel for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit

Notice regarding forward-looking statements:

Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, are assumptions regarding our future operational results. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the Company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our final prospectus which is available at Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Contact Information